Systemic immunological changes following intravenous mesenchymal stromal cell infusion in stable COPD patients

Armitage, Jesse D.; Tan, Dino B.A.; Troedson, Russel; Young, Paul R.; Lam, Kay-Vin; Shaw, Kathryn; Sturm, M.; Weiss, Daniel; Moodley, Yuben

doi:10.1183/13993003.congress-2018.oa1653

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, several approaches have been proposed to improve the effectiveness, endurance and therapeutic efficiency of MSCs [28,29]. Worth mentioning, the approaches utilizing MSCs, and especially the primed MSCs, could be vital for the success of cell therapy in lung complications, as the intravenously infused MSCs often get trapped in the lung; however, the retention time of MSCs within the lung is extremely short [30]. Though, the alteration in holding capacity of lung in a diseased scenario cannot be ruled out.…”

mentioning

confidence: 99%

‘Primed’ Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients

Raza

Seth

Khan

2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

The COVID19 pandemic, designated as a public health crisis by the World Health Organization (WHO), is rapidly spreading around the world impacting the health and economy of almost all the countries. The data of hospitalized COVID19 patients, especially those with serious illness, indicate the involvement of immunopathological complications. As no effective treatment is currently available, we propose 'Primed' Mesenchymal Stem Cells (MSCs) as a therapeutic alternative to tackle devastating epidemic. The individual response to MSCs treatment is heterogeneous. During the treatment of infectious pathology, the effectiveness of the treatment may vary based on the disease scenario. Interestingly, when transplanted in vivo, MSCs are governed by the locally regulated microenvironment, suggesting that the restorative variability could be tailored by choosing a priming regimen to specifically correct a given pathology. Therefore, in our opinion, the priming of MSCs could be a novel approach to improve the responses of COVID19 patients. Keywords COVID19. Coronavirus. SARS-CoV-2. Mesenchymal stem cells. MSC priming. Immunomodulation Main Over the past 5 months, the coronavirus disease 2019 (COVID19) pandemic has relentlessly impacted the global population. The first case of COVID19 infection was identified in the Wuhan City of China on December 1, 2019. Since then, the virus has spread to 213 countries and territories, resulting in over 5.3 million confirmed cases and over 340,000 deaths as on May 23, 2020 (https://www. worldometers.info/coronavirus/). People of all ages are vulnerable to COVID19 infection; however, those over 60 years of age and with pre-existing medical conditions, such as cardiovascular disease, diabetes, or high blood pressure, are more prone to fall seriously ill and succumb to the disease. According to the Centers for Disease Control and Prevention,

show abstract

mentioning

confidence: 99%

‘Primed’ Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients

Raza

Seth

Khan

2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

show abstract

“…Future therapies might enable the normalization of the diseased matrix, a particular problem in the context of cell therapy as delivering cells to a disease niche may limit the efficiency of engraftment and the efficacy of therapies. There is some evidence for this concept from in vitro studies of recellularized lung scaffolds, where donor age and disease status affects the efficiency of re-seeding (65) and from MSC infusions in patients, where lungs with milder disease retain MSCs for longer (66).…”

Section: Future Cell Therapies For Lung Diseasementioning

confidence: 99%

National Heart, Lung, and Blood Institute and Building Respiratory Epithelium and Tissue for Health (BREATH) Consortium Workshop Report: Moving Forward in Lung Regeneration

Hynds

Zacharias

Nikolić

et al. 2021

Am J Respir Cell Mol Biol

View full text Add to dashboard Cite

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, along with the Longfonds BREATH consortium convened a working group to review the field of lung regeneration and suggest avenues for future research. The meeting took place on May 22, 2019 at the American Thoracic Society 2019 conference in Dallas, Texas, USA, and brought together investigators studying lung development, adult stem cell biology, induced pluripotent stem cells, biomaterials and respiratory disease. The purpose of the working group was 1) to examine the present status of basic science approaches to tackling lung disease and promoting lung regeneration in patients and 2) to determine priorities for future research in the field.

show abstract

“…Following systemic administration, MSCs primarily lodge in the pulmonary capillary system, through as yet poorly understood interactions with the endothelium. They do not engraft and are cleared by a range of host immune mechanisms over 1-2 days, although available data suggests that they may persist for up to 3-4 days in the setting of lung inflammation (Allers et al, 2004;Armitage et al, 2018). MSCs express a range of danger and molecular pathogen cell surface receptors, including the Toll-Like receptors and a growing body of literature demonstrates that while in the pulmonary capillary bed, the MSCs respond to specific inflammatory environments by releasing different portfolios of mediators (Romieu-Mourez et al, 2009;Waterman et al, 2010;Kusuma et al, 2017;Abreu et al, 2019;Islam et al, 2019;Enes et al, 2021;Galipeau et al, 2021).…”

mentioning

confidence: 99%

What is the need and why is it time for innovative models for understanding lung repair and regeneration?

Weiss

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Advances in tissue engineering continue at a rapid pace and have provided novel methodologies and insights into normal cell and tissue homeostasis, disease pathogenesis, and new potential therapeutic strategies. The evolution of new techniques has particularly invigorated the field and span a range from novel organ and organoid technologies to increasingly sophisticated imaging modalities. This is particularly relevant for the field of lung biology and diseases as many lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic fibrosis (IPF), among others, remain incurable with significant morbidity and mortality. Advances in lung regenerative medicine and engineering also offer new potential avenues for critical illnesses such as the acute respiratory distress syndrome (ARDS) which also continue to have significant morbidity and mortality. In this review, an overview of lung regenerative medicine with focus on current status of both structural and functional repair will be presented. This will serve as a platform for surveying innovative models and techniques for study, highlighting the need and timeliness for these approaches.

show abstract

Systemic immunological changes following intravenous mesenchymal stromal cell infusion in stable COPD patients

Cited by 3 publications

References 0 publications

‘Primed’ Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients

‘Primed’ Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients

National Heart, Lung, and Blood Institute and Building Respiratory Epithelium and Tissue for Health (BREATH) Consortium Workshop Report: Moving Forward in Lung Regeneration

What is the need and why is it time for innovative models for understanding lung repair and regeneration?

Contact Info

Product

Resources

About